# SHL Telemedicine

2017 Results

27 March 2018







### Forward looking statements

This presentation contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you not to place undue reliance on forward-looking statements, which reflect our analysis only and speak only as of the date of this presentation. We undertake no obligation to publicly update the forward-looking statements to reflect subsequent events or circumstances.

This presentation contains trade names, trademarks and service marks of other companies. We do not intend our use or display of other parties' trade names, trademarks and service marks to imply a relationship with, or endorsement or sponsorship of, these other parties.

## Agenda

- Financial Highlights and Summary
- Business Update
- Appendix





### 2017 Financial Highlights

- After a couple of years of losses the company is back to profitability with a net profit result of \$ 2.4
  m
- Company moves from cash burning to generating cash with a positive free cash flow of \$ 10.5 m (\$ 1.3 m excluding bonus income and extraordinary income)
- Revenues for the year are up from 3.9% to \$ 37 m stable in constant currency :
  - Slight revenue decline in Israel (2%) due to decrease subscribers base and institutional patients in the chronic disease monitoring programs
  - Stable income in Germany operations (Y2Y excluding bonus incomes)
  - Bonus income in Germany from PBC customer in the amount of \$ 0.4 m
- Continued streamlining of businesses and efficiency improvements expands the gross margin to 51.9% (compared to 46.4% in 2016) excluding revenue adjustments.
- Positive EBITDA of \$ 8.6 m
- Cash reserves remain stable after repayment of loans and interest of \$ 12.2 m



## 2017 Financial Summary


USD million	As reported			Constant Currency*		
	2017	2016	% change	2017	2016	% change
Revenues	37.4	40.5	(7.7%)	35.7	40.5	(11.9%)
Germany	16.7	20.7	(19.3)	16.3	20.7	(21.3)
Israel	20.5	19.6	4.6%	19.2	19.6	(2.0%)
ROW	0.2	0.2	-	0.2	0.2	-
EBIT (LBIT)	4.1	(4.8)	n.a.	3.9	(4.8)	n.a.
% of revenues	11%	n.a		11%	n.a	
Net profit (loss)	2.4	(11.1)	n.a.	2.3	(11.1)	n.a.
% of revenues	6.4%	n.a.		6.4%	n.a.	
EBITDA	8.6	1.0	760%	8.4	1.0	740%
% of revenues	23%	2.5%		23.5%	2.5%	
EPS (LPS)	0.23	(1.06)	n.a.	0.22	(1.06)	n.a.


<sup>\*</sup>Presenting figures in constant currency gives more meaningful comparison between the periods due to fluctuations in NIS/USD/EUR exchange rates.



### 31.12.2017 Balance Sheet

#### **USD Million**







## 2017 Cash Flow Summary

USD million	2017	2016	Diff.
Cash received from (used in) operating activities	12.0	(0.4)	12.4
Cash used in investing activities (ex. marketable securities)	(1.5)	(1.4)	(0.1)
Cash received (used) in financing activities	(11.3)*	3.8**	(15.1)
Effect of exchange rate changes	0.7	(0.1)	0.8
Increase (decrease) in cash, cash equivalents & marketable securities	(0.1)	1.9	(2.0)
Cash, cash equivalents & marketable securities at beginning of period	10.5	8.6	1.9
Cash, cash equivalents & marketable securities at end of period	10.4	10.5	(0.1)
Free Cash Flow	10.5	(1.8)	12.3

<sup>\*</sup>Early repayment of loan in Germany (EUR 6.1) + current loan repayments in Israel

<sup>\*\*</sup>Loan in Germany net of repayments in Germany and Israel



### **Business Update**



- Strategic priorities:
  - Continuing to develop our existing platforms in Germany and Israel
  - Introducing new programs and technologies to enhance customer value add and attract new customers
  - Growing the smartheart™ business globally
  - Maintaining a streamlined organization



### **Investor Information**

 10,878,491 registered shares with a par value of NIS 0.01 each

Listed at SIX Swiss Exchange in CHF;
 Symbol: SHLTN, No. 1128957

Price high/low (CHF) 7.93/6.25

Market cap high/low (CHF m) 83.2/65.6

Market cap 30.12.17 (CHF m) 66.2

No voting restrictions



Yoav Rubinstein, CEO yoavr@shl-telemedicine.com

Yoav Rubinstein joined SHL in March 2012 as Senior Vice President, Head of Global Business Development and was appointed CEO in June 2017. Before joining SHL, Mr. Rubinstein worked in the private equity industry, for 9.5 years as a Principal for Apax Partners and then as a Senior Advisor to Saban Capital Group. Mr. Rubinstein holds a BA in Business Administration from the Interdisciplinary Center, Israel.



Yossi Vadnagra, CFO yossiv@shl-telemedicine.com

Yossi joined SHL in February 2017 as Director of Business Development in Israel and has been appointed CFO in June 2017. Over 18 years of experience in international markets with Blue Chip companies as CFO in the Healthcare, Retail, and Engineering sectors. He is a CPA (Israel) with an MBA in Finance.

# Thank you



